Senior Merck Executive to Head
IAVI’s AIDS Vaccine Design and Development Laboratory
August 10, 2010
New York, August 10, 2010 — The International AIDS Vaccine Initiative (IAVI) is pleased to
announce the appointment of Michael Caulfield as Executive Director of the IAVI
AIDS Vaccine Design and Development Laboratory (DDL).
Dr. Caulfield comes to IAVI from Merck, where he worked for 16 years, joining as a research
fellow and rising to become Senior Director of Vaccine Basic Research. An immunologist by training, Caulfield
contributed to the development of a number of vaccines and technologies while
at Merck. Prior to that, he spent 14 years as an academic researcher at the
renowned Cleveland Clinic. He received his BS and PhD from the University of
Notre Dame prior to training as a postdoctoral fellow at the Harvard School of
Public Health.
“We are very excited to have Mike on board
as Executive Director of the DDL,” said Dr. Seth Berkley, President and CEO of
IAVI. “He brings to the position a set of skills and a depth of experience that
will serve IAVI well as we move more aggressively into the design of new
classes of HIV vaccines. Not only has he demonstrated talent for managing
innovation in biomedical research—a rare skill in itself—but his background has
uniquely prepared him for the sort of work we’re focusing on at IAVI.”
Caulfield started out at Merck researching
vaccines against viruses such as hepatitis B, influenza, and HIV, and he contributed
significantly to the development of Zostavax®, a vaccine for the control of
shingles. He also devised novel methods to assess the immune response to
candidate HIV vaccines based on DNA and adenovirus vector technologies. In
2005, he took the helm of the microbial vaccine group, researching preventive
vaccines against bacterial diseases. In that role, he led the preclinical
development of a 15-component pneumococcal conjugate vaccine against
Streptococcus pneumoniae, an agent that causes significant co-morbidity with
HIV, especially in the developing world.
“I am very excited to join IAVI and to
share in its mission to develop AIDS vaccines,” said Caulfield. “I look forward
to continuing to work on a problem of such great significance to the world—and
to be joining a team of expert researchers in the field.”
Caulfield will be responsible for leading
the DDL in its role as IAVI’s hub of translational research and vaccine
discovery. The DDL boasts an enviable
roster of scientists involved in the design of replication-competent viral
vectors and the formulation and testing of immunogens developed to elicit
potentially protective immune responses to HIV. Caulfield will also augment an
R&D team that already has significant experience with industry standard
approaches to portfolio and project management.
“Mike’s joining at a critical time for the
field,” said Dr. Wayne Koff, IAVI’s Chief Scientific Officer. “We’re in the
middle of a renaissance in AIDS vaccine design and development. IAVI aims to
capitalize on recent advances by expanding and integrating the operations of
its three core laboratories: the Neutralizing Antibody Center at The Scripps
Research Institute, which is identifying new approaches to designing HIV
vaccines, the DDL, which is translating these research leads into clinical
candidates, and the Human Immunology Lab at Imperial College London, which is
assessing the immune responses of candidate vaccines in clinical trials. Their
coordinated efforts will be further linked up with those of IAVI’s extended
network of collaborating AIDS vaccine research centers in sub-Saharan Africa
and India.”
About IAVI
The International AIDS Vaccine Initiative
(IAVI) is a global not-for-profit organization whose mission is to ensure the
development of safe, effective, accessible, preventive HIV vaccines for use
throughout the world. Founded in 1996 and operational in 25 countries, IAVI and
its network of collaborators research and develop vaccine candidates. IAVI was founded with the generous support of
the Alfred P. Sloan Foundation, The Rockefeller Foundation, The Starr
Foundation, and Until There's A Cure Foundation. Other major supporters include the Bill & Melinda Gates Foundation, the Foundation for the
National Institutes of Health, The John D. Evans Foundation, The New York
Community Trust, the James B. Pendleton Charitable Trust; the Governments of
Canada, Denmark, India, Ireland, Japan, The Netherlands, Norway, Spain, Sweden,
the United Kingdom, and the United States, the Basque Autonomous Government
(Spain), the European Union as well as the National Institute of Allergy and
Infectious Diseases and The City of New York, Economic Development Corporation;
multilateral organizations such as The World Bank and The OPEC Fund for International
Development; corporate donors including BD (Becton, Dickinson & Co.),
Bristol-Myers Squibb, Continental Airlines, Google Inc., Pfizer Inc, and Thermo
Fisher Scientific Inc.; leading AIDS charities such as Broadway Cares/Equity
Fights AIDS; and many generous individuals from around the world. For more information, see www.iavi.org.
Merck
Margaret
G. McGlynn was the division president for Merck,
and is the president & CEO for International AIDS Vaccine
Initiative (IAVI).
Note: Adel
A.F. Mahmoud was the chief medical adviser for Merck,
and is a director at the International AIDS Vaccine
Initiative (IAVI).
Alice
P. Albright is a director at the International AIDS Vaccine
Initiative (IAVI), and Madeleine K.
Albright’s daughter.
Madeleine
K. Albright is Alice P. Albright’s
mother, a director at the Center for American
Progress, a trustee at the Aspen Institute (think
tank), an overseer at the International Rescue
Committee, and an honorary director at the Atlantic
Council of the United States
(think tank).
Foundation
to Promote Open Society was a funder for the Center for
American Progress, the Aspen Institute (think
tank), the International Rescue
Committee, the Committee for Economic
Development, the NAACP Legal Defense &
Educational Fund, and the Brookings Institution
(think tank).
George Soros
was a supporter for the Center for American
Progress, is the chairman for the Foundation
to Promote Open Society, and the Open Society
Foundations.
Open
Society Foundations was a funder for the Center for
American Progress, the Atlantic Council of the United States
(think tank), and the American Constitution
Society.
Eric H.
Holder Jr. was an intern at the NAACP Legal Defense &
Educational Fund, a board member for the American
Constitution Society, Merck was his
client, and is the attorney general at the U.S. Department of Justice
for the Barack Obama administration.
Bill
& Melinda Gates Foundation was a funder for the Center for
American Progress, the Aspen Institute (think
tank), the International Rescue
Committee, the Committee for Economic
Development, the United Negro College Fund,
and the Brookings Institution (think tank).
Geoffrey
Lamb is the president, global policy & advocacy for the Bill & Melinda Gates Foundation, and a director at the International AIDS Vaccine Initiative (IAVI).
Patricia
F. Russo is a trustee at the Committee for Economic
Development, and a director at Merck.
Donna S.
Morea was a trustee at the Committee for Economic
Development, and the EVP for the CGI Group
Inc.
CGI
Group Inc. was the Obamacare
contractor that developed Healthcare.gov web site.
Obamacare
is Barack Obama’s signature policy
initiative.
Barbara
G. Fast was a VP for the CGI Group Inc.,
and a VP at the Boeing Company.
W.
James McNerney Jr. is the chairman & president & CEO for the Boeing Company,
the chairman for the President's Export Council,
and a member of the Commercial Club of Chicago.
Kenneth
C. Frazier is a member of the President's Export Council,
and the chairman & president & CEO for Merck.
R. Eden
Martin is the president of the Commercial Club of Chicago,
and counsel at Sidley Austin LLP.
Michelle
Obama was a lawyer at Sidley Austin LLP.
Barack Obama
was an intern at Sidley Austin LLP.
Newton N.
Minow is a senior counsel at Sidley Austin LLP,
and a member of the Commercial Club of Chicago.
Linda
Johnson Rice is a member of the Commercial Club of Chicago,
a director at the United Negro College Fund,
and a friend of Valerie B. Jarrett.
Richard
T. Clark was a director at the United Negro College Fund,
and the chairman for Merck.
Akin,
Gump, Strauss, Hauer & Feld, LLP was the lobby firm for Merck, and a funder for the Center for
American Progress.
Vernon E. Jordan Jr. is a
senior counsel for Akin, Gump, Strauss, Hauer
& Feld, LLP, an honorary trustee at the Brookings Institution (think tank), Valerie B. Jarrett’s great uncle, a director at the American
Friends of Bilderberg (think
tank), and a 2008 Bilderberg conference
participant (think tank).
Cyrus
F. Freidheim Jr. is an honorary trustee at the Brookings
Institution (think tank), and a member of the Commercial
Club of Chicago.
Commercial Club of Chicago, Members Directory
A-Z (Past Research)
Tuesday, December 17, 2013
Valerie
B. Jarrett is a member of the Commercial Club of Chicago,
the senior adviser for the Barack Obama
administration, and her great uncle is Vernon E.
Jordan Jr.
Rahm I.
Emanuel is a member of the Commercial Club of Chicago,
the Chicago (IL) mayor, Ezekiel Emanuel’s brother, and was the White House chief of
staff for the Barack Obama administration.
Ezekiel
Emanuel is Rahm I. Emanuel’s brother, a senior fellow at the Center for American Progress, and was the health care policy
adviser for the Barack Obama administration.
Madeleine
K. Albright is a director at the Center for American
Progress, and is Alice P. Albright’s mother.
Alice
P. Albright is Madeleine K.
Albright’s
daughter, and a director at the International
AIDS Vaccine Initiative (IAVI).
Adel
A.F. Mahmoud is a director at the International AIDS Vaccine
Initiative (IAVI), and was the chief medical
adviser for Merck.
Margaret
G. McGlynn was the division president for Merck,
and is the president & CEO for International AIDS Vaccine
Initiative (IAVI).
No comments:
Post a Comment